Global Trends in Immunotherapy Research on Breast Cancer over the Past 10 Years.
Global Trends in Immunotherapy Research on Breast Cancer over the Past 10 Years.
复制标题
DOI：
10.1155/2020/4708394
复制
发表时间：
2020
影响因子：
--
通讯作者：
Hwang JW
中科院分区：
文献类型：
--
作者：
Ahn SK;Hwang JW
近年来，许多研究都集中在宿主免疫系统及其与多种实体瘤（包括乳腺癌）肿瘤进展的关系上。本研究调查了乳腺癌免疫治疗研究的最新趋势，并比较了不同地区、机构和作者的研究贡献。在 Web of Science 数据库中对 2010 年至 2019 年发表的乳腺癌和免疫治疗研究（使用不同的关键词组合）进行了检索。收集文献计量数据进行分析。利用VOSviewer软件生成关键词共现网络图，实现网络可视化分析。共查明 1,041 种出版物。美国和中国贡献了约 50% 的出版物，分别为 336 份和 208 份。两国在 2015 年之后推动了出版物的增加。 Nanda 等人在《临床肿瘤学杂志》上发表了一篇题为“Pembrolizumab 用于晚期三阴性乳腺癌患者：IB 期 KEYNOTE-012 研究”的论文。被引用最多（715 次引用）。这项研究中发现的关键词分为四类：“机制”、“疫苗接种”、“PD-L1”和“化疗”。 “肿瘤浸润淋巴细胞”和“PD-1/PD-L1”是最新的热点，大多出现在2017年。作者关键词分析显示，近期乳腺癌免疫治疗的趋势集中在三阴性乳腺癌亚型、PD-1/PD-L1免疫检查点通路和抑制剂上。本研究分析了近10年来全球乳腺癌免疫治疗研究趋势，深入剖析了本期文章的特点和研究热点。
In recent years, many studies have focused on the host immune system and its relationship with tumor progression in a variety of solid tumors, including breast cancer. This study investigates recent trends of immunotherapy research in breast cancer and compares the contributions of research from different regions, institutions, and authors. A search of breast cancer and immunotherapy studies that were published between 2010 and 2019—with different keyword combinations—was performed in the Web of Science database. Bibliometric data were collected for analysis. VOSviewer software was used to generate a figure for the keyword's co-occurrence network, so as to implement network visualization analysis. A total of 1,041 publications were identified. The United States and China contributed to approximately 50% of the publications, 336 and 208, respectively. Both countries drove the increase in publications after 2015. A paper entitled “Pembrolizumab in patients with advanced triple-negative breast cancer: Phase IB KEYNOTE-012 Study” that was published in the Journal of Clinical Oncology by Nanda et al. was the most cited (715 citations). The keywords found in this research were grouped into four clusters: “mechanism,” “vaccination,” “PD-L1,” and “chemotherapy.” The terms “tumor-infiltrating lymphocytes” and “PD-1/PD-L1” are among the latest hotspots, which mostly appeared in 2017. Author keyword analysis revealed that recent trends in breast cancer immunotherapy focus on the triple-negative breast cancer subtype and PD-1/PD-L1 immune checkpoint pathway and inhibitors. This study analyzed global trends in immunotherapy research on breast cancer over the past 10 years and provided insight into the features and research hotspots of the articles in this issue.